These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
164 related items for PubMed ID: 23979426
1. Advanced glycation end products suppress lysyl oxidase and induce bone collagen degradation in a rat model of renal osteodystrophy. Aoki C, Uto K, Honda K, Kato Y, Oda H. Lab Invest; 2013 Nov; 93(11):1170-83. PubMed ID: 23979426 [Abstract] [Full Text] [Related]
2. Role of TGF-β in a mouse model of high turnover renal osteodystrophy. Liu S, Song W, Boulanger JH, Tang W, Sabbagh Y, Kelley B, Gotschall R, Ryan S, Phillips L, Malley K, Cao X, Xia TH, Zhen G, Cao X, Ling H, Dechow PC, Bellido TM, Ledbetter SR, Schiavi SC. J Bone Miner Res; 2014 Nov; 29(5):1141-57. PubMed ID: 24166835 [Abstract] [Full Text] [Related]
3. Collagen advanced glycation inhibits its Discoidin Domain Receptor 2 (DDR2)-mediated induction of lysyl oxidase in osteoblasts. Khosravi R, Sodek KL, Faibish M, Trackman PC. Bone; 2014 Jan; 58():33-41. PubMed ID: 24120383 [Abstract] [Full Text] [Related]
4. Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7. González EA, Lund RJ, Martin KJ, McCartney JE, Tondravi MM, Sampath TK, Hruska KA. Kidney Int; 2002 Apr; 61(4):1322-31. PubMed ID: 11918739 [Abstract] [Full Text] [Related]
5. The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Rojas E, Carlini RG, Clesca P, Arminio A, Suniaga O, De Elguezabal K, Weisinger JR, Hruska KA, Bellorin-Font E. Kidney Int; 2003 May; 63(5):1915-23. PubMed ID: 12675872 [Abstract] [Full Text] [Related]
6. Effects of Advanced Glycation End Products on Differentiation and Function of Osteoblasts and Osteoclasts. Park SY, Choi KH, Jun JE, Chung HY. J Korean Med Sci; 2021 Sep 27; 36(37):e239. PubMed ID: 34581519 [Abstract] [Full Text] [Related]
7. Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia. Tamagaki K, Yuan Q, Ohkawa H, Imazeki I, Moriguchi Y, Imai N, Sasaki S, Takeda K, Fukagawa M. Nephrol Dial Transplant; 2006 Mar 27; 21(3):651-9. PubMed ID: 16311258 [Abstract] [Full Text] [Related]
8. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats. Meng Y, Zhang H, Li Y, Li Q, Zuo L. Bone; 2014 Jan 27; 58():168-76. PubMed ID: 24145307 [Abstract] [Full Text] [Related]
9. Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy. Yamamoto T, Ozono K, Miyauchi A, Kasayama S, Kojima Y, Shima M, Okada S. Am J Kidney Dis; 2001 Oct 27; 38(4 Suppl 1):S161-4. PubMed ID: 11576945 [Abstract] [Full Text] [Related]
10. Development of a novel chronic kidney disease mouse model to evaluate the progression of hyperphosphatemia and associated mineral bone disease. Tani T, Orimo H, Shimizu A, Tsuruoka S. Sci Rep; 2017 May 22; 7(1):2233. PubMed ID: 28533541 [Abstract] [Full Text] [Related]
11. Glycosaminoglycan, collagen, and glycosidase changes in human osteoblasts treated with interleukin 1, and osteodystrophy. Stabellini G, Minola E, Dolci C, Moscheni C, Calastrini C, Lumare E, Tartaglia G, Carinci F, Vertemati M. Biomed Pharmacother; 2007 Dec 22; 61(10):686-92. PubMed ID: 17561366 [Abstract] [Full Text] [Related]
12. Surgically induced uremia in rats. I: Effect on bone strength and metabolism. Jablonski G, Klem KH, Attramadal A, Dahl E, Rønningen H, Gautvik KM, Haug E, Gordeladze JO. Biosci Rep; 1993 Oct 22; 13(5):275-87. PubMed ID: 8142613 [Abstract] [Full Text] [Related]
13. A role for lysyl oxidase regulation in the control of normal collagen deposition in differentiating osteoblast cultures. Hong HH, Pischon N, Santana RB, Palamakumbura AH, Chase HB, Gantz D, Guo Y, Uzel MI, Ma D, Trackman PC. J Cell Physiol; 2004 Jul 22; 200(1):53-62. PubMed ID: 15137057 [Abstract] [Full Text] [Related]
14. Effects of triangle grass decoction on bone metabolism in rats with chronic kidney disease complicated with mineral and bone abnormalities. Liu L, Wang L, Li L, Wang H, Yuan L, Kang L, Jiang Q, Chen G, Lv N, Cui X, Huang L, Wu H, Xu J, Li Y. J Ethnopharmacol; 2021 Jul 15; 275():114126. PubMed ID: 33872749 [Abstract] [Full Text] [Related]
15. Bone morphogenetic protein-2 restores mineralization in glucocorticoid-inhibited MC3T3-E1 osteoblast cultures. Luppen CA, Smith E, Spevak L, Boskey AL, Frenkel B. J Bone Miner Res; 2003 Jul 15; 18(7):1186-97. PubMed ID: 12854828 [Abstract] [Full Text] [Related]
16. Lysyl oxidase propeptide inhibits FGF-2-induced signaling and proliferation of osteoblasts. Vora SR, Palamakumbura AH, Mitsi M, Guo Y, Pischon N, Nugent MA, Trackman PC. J Biol Chem; 2010 Mar 05; 285(10):7384-93. PubMed ID: 20048148 [Abstract] [Full Text] [Related]
17. Expression of lysyl oxidase isoforms in MC3T3-E1 osteoblastic cells. Atsawasuwan P, Mochida Y, Parisuthiman D, Yamauchi M. Biochem Biophys Res Commun; 2005 Feb 25; 327(4):1042-6. PubMed ID: 15652501 [Abstract] [Full Text] [Related]
18. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Ishii H, Wada M, Furuya Y, Nagano N, Nemeth EF, Fox J. Bone; 2000 Feb 25; 26(2):175-82. PubMed ID: 10678413 [Abstract] [Full Text] [Related]
19. Bazedoxifene Ameliorates Homocysteine-Induced Apoptosis and Accumulation of Advanced Glycation End Products by Reducing Oxidative Stress in MC3T3-E1 Cells. Kanazawa I, Tomita T, Miyazaki S, Ozawa E, Yamamoto LA, Sugimoto T. Calcif Tissue Int; 2017 Mar 25; 100(3):286-297. PubMed ID: 27832315 [Abstract] [Full Text] [Related]
20. Advanced glycation end products accelerate rat vascular calcification through RAGE/oxidative stress. Wei Q, Ren X, Jiang Y, Jin H, Liu N, Li J. BMC Cardiovasc Disord; 2013 Mar 05; 13():13. PubMed ID: 23497312 [Abstract] [Full Text] [Related] Page: [Next] [New Search]